





authors declare that no
competing interests exist.
Funding: See page 26
Received: 15 April 2020
Accepted: 15 October 2020





al. This article is distributed under
the terms of the Creative
Commons Attribution License,
which permits unrestricted use
and redistribution provided that
the original author and source are
credited.
Macrophages promote endothelial-to-
mesenchymal transition via MT1-MMP/
TGFb1 after myocardial infarction
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Abstract Macrophages (Mjs) produce factors that participate in cardiac repair and remodeling
after myocardial infarction (MI); however, how these factors crosstalk with other cell types
mediating repair is not fully understood. Here we demonstrated that cardiac Mjs increased the
expression of Mmp14 (MT1-MMP) 7 days post-MI. We selectively inactivated the Mmp14 gene in
Mjs using a genetic strategy (Mmp14f/f:Lyz2-Cre). This conditional KO (MAC-Mmp14 KO) resulted
in attenuated post-MI cardiac dysfunction, reduced fibrosis, and preserved cardiac capillary
network. Mechanistically, we showed that MT1-MMP activates latent TGFb1 in Mjs, leading to
paracrine SMAD2-mediated signaling in endothelial cells (ECs) and endothelial-to-mesenchymal
transition (EndMT). Post-MI MAC-Mmp14 KO hearts contained fewer cells undergoing EndMT than
their wild-type counterparts, and Mmp14-deficient Mjs showed a reduced ability to induce EndMT
in co-cultures with ECs. Our results indicate the contribution of EndMT to cardiac fibrosis and
adverse remodeling post-MI and identify Mj MT1-MMP as a key regulator of this process.
Introduction
Although the mortality rate from cardiovascular disease (CVD) has declined over the last 50 years,
myocardial infarction (MI) continues to be one of the most lethal diseases worldwide, and many
pathologies arise from adverse remodeling after cardiac injury (e.g. heart failure and cardiac rupture)
(Benjamin et al., 2017). Therefore, new strategies are urgently needed to improve cardiac repair
and function after MI. MI is usually provoked by plaque rupture in a coronary artery, resulting in
insufficient oxygen supply to the myocardium, which undergoes necrosis. The onset of MI triggers a
cascade of events, including cardiomyocyte (CM) death, acute inflammation, angiogenesis, and scar
formation (Frangogiannis, 2015). Cardiac healing is impaired by both excessive and insufficient
expansion of macrophages (Mjs), prompting interest in the potential of Mjs as therapeutic targets
for CVD (Dick et al., 2019; Panizzi et al., 2010; van Amerongen et al., 2007). Nonetheless, the
exact Mj phenotypes and mechanisms that might enhance tissue repair are not clearly defined.
We and others have shown that post-injury Mjs are distinct from resident cardiac Mjs
(Bajpai et al., 2019; Dick et al., 2019; Walter et al., 2018). Monocytes and Mjs are sequentially
mobilized from bone marrow (BM) and spleen to the infarcted myocardium (Nahrendorf et al.,
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2007; Swirski et al., 2009). During day 1 to day 4 after injury, Ly6Chigh inflammatory Mjs clear
necrotic cellular debris and damaged extracellular matrix (ECM) from the tissue and attract other
immune cells through the secretion of pro-inflammatory cytokines (TNFa, IL1b, and IL6) that further
fuel inflammation. Over the course of several days, the inflammatory phase gives way to a healing
phase, dominated by the second wave of Mjs, this time Ly6Clow reparative Mjs with the capacity to
dampen inflammation, promote ECM reconstruction, and angiogenesis. These latter Mjs are charac-
terized by the secretion of anti-inflammatory (IL10), angiogenic (VEGF), and pro-fibrotic (TGFb1) fac-
tors, as well as matrix metalloproteinases (MMPs), which promote tissue remodeling
(Nahrendorf et al., 2007; Walter et al., 2018). However, how these factors produced by Mjs cross-
talk with other cell types and orchestrate cardiac repair is still not fully elucidated.
MMPs are a family of zinc-dependent endopeptidases that have been traditionally associated
with the degradation and turnover of ECM components. MMPs are now known to, directly and indi-
rectly, regulate cell behavior and microenvironment through the proteolytic processing of a large
variety of molecules, such as membrane receptors and growth factors (Page-McCaw et al., 2007).
Membrane type 1 matrix metalloproteinase (MT1-MMP/Mmp14) was the first membrane-anchored
MMP to be described (Sato et al., 1994), and the cell surface location provides this enzyme with
exclusive functions affecting cellular behavior. MT1-MMP is involved in the degradation of a spec-
trum of structural matrix proteins (including collagens I, II, and III, fibronectin, and laminin), the pro-
teolytic processing of growth factors and cytokines (e.g. TGFb and SDF-1), and the activation of
other MMPs (e.g. pro-MMP2), expanding MT1-MMP functional pleiotropism.
Previous studies pointed out a deleterious role of MT1-MMP in post-MI cardiac remodeling,
mostly related to its collagenase activity in fibroblasts (FBs) (Koenig et al., 2012). Nevertheless, spe-
cific Mj MT1-MMP contribution to cardiac healing response has never been addressed. In this study,
we demonstrate that Mj-restricted Mmp14 inactivation attenuates post-MI left ventricular (LV) dys-
function by preventing endothelial-to-mesenchymal transition (EndMT), maybe accompanied by
other concomitant processes, and propose new treatment options for cardiac ischemic disease
based on the modulation of Mj MT1-MMP activity.
Results
MI induced the expression of Mmp14 in Mjs
To gain insight into the potential contribution of Mj-produced MT1-MMP to cardiac healing, we
induced MI in adult mice by permanent coronary ligation (LAD-ligation). Using an established gating
strategy (Walter et al., 2018), we isolated cardiac Mjs at 0, 3, 7, and 28 days post-MI (Figure 1—
figure supplement 1A–B) and assessed gene expression related to ECM remodeling (Figure 1A).
MI induced expression of Mmp14 (MT1-MMP) and its substrates Mmp2 and Col1a1 in Mjs in the
heart, reaching maximum levels of expression on day 7 post-MI. In contrast, other MMP family mem-
bers (Mmp9 and Mmp13) were downregulated after infarction.
Mj-restricted MT1-MMP deficiency attenuates LV dysfunction and
dilation and reduces collagen deposition after MI
To explore the role of Mj-derived MT1-MMP in post-MI LV function and remodeling, we generated
a Mj-specific KO mouse for Mmp14. Lyz2-Cre mice (Clausen et al., 1999) were crossed with
Mmp14f/f mice (Gutiérrez-Fernández et al., 2015), resulting in the deletion of exons 4 and 5 in the
floxed Mmp14 allele in MAC-Mmp14 KO mice (Cre+ mice) (Figure 1—figure supplement 2A).
Mmp14f/f littermates (Cre-) were used as WT controls. No significant differences in either baseline
cardiac function (Table 1) or in circulating monocytes and neutrophils were found between geno-
types (Table 2, and Figure 1—figure supplement 2B–C). Mmp14 was efficiently inactivated in BM-
derived Mjs (BMDMs) and in cardiac Mjs sorted from 7-day-post-MI MAC-Mmp14 KO hearts; in
contrast, Mmp14 expression did not differ between endothelial cells (ECs) purified from WT and
MAC-Mmp14 KO 7-day-post-MI hearts (Figure 1—figure supplement 2D). The low-efficiency
recombination of the Lyz2-Cre system in monocytes and dendritic cells (Abram et al., 2014) and the
lack of Mmp14 expression in neutrophils (Daseke et al., 2019) make this MAC-Mmp14 KO mouse a
suitable model to study Mj-MT1-MMP role in post-MI LV remodeling and function.
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Figure 1. Mj-restricted MT1-MMP deficiency attenuates LV dysfunction and dilation and reduces collagen deposition after MI. (A) mRNA expression
levels of genes related to ECM-remodeling assessed by qPCR in sorted Mjs at the indicated post-MI stages. Data are means ± SEM of three
independent pools of 3–5 mice per time point. One-way ANOVA followed by Tukey’s multiple comparisons test. (B) Representative LV M-mode long-
axis echocardiography views at end-diastole on day 0 and day 28 post-MI in WT and MAC-Mmp14 KO mice. (C, D) Post-MI progression of LVEF and
Figure 1 continued on next page
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Echocardiography revealed that Mj-inactivation of Mmp14 ameliorated LV dysfunction and pre-
vented LV dilation post-MI, with MAC-Mmp14 KO mice having a significantly higher LV ejection frac-
tion (LVEF) and lower LV end-diastolic volume (LVVold) (Figure 1B–C, and Video 1). Infarct size and
LV wall motion score index (WMSI) were calculated to assess global and regional cardiac contractility
abnormalities by echocardiography (see Materials and methods). This analysis showed that LAD-liga-
tion produced smaller infarcts and a lower WMSI in MAC-Mmp14 KO mice (Figure 1D–E), indicating
better preservation of cardiac function and less pronounced wall-motion abnormalities in the LV
when Mj MT1-MMP was absent.
MT1-MMP can process a variety of ECM components, so we next analyzed the fibrotic response
to MI. Transverse sections of 28-day-post-MI hearts were assessed using a multi-photon laser scan-
ning microscope to capture multi-photon autofluorescence (MPEF) and second harmonic generation
(SHG) signals, allowing simultaneous visualization of myocyte components and fibrillary collagen,
Figure 1 continued
LVVold (C) and infarct size (percentage of LV with contractility alterations) and WMSI (D) assessed by echocardiography. Data are means ± SEM of 9–10
mice per genotype. Two-way ANOVA followed by Tukey’s multiple comparisons test. (E) Quantitative assessment of LV contractility at 28 days post-MI,
showing mean scores for every LV segment at the basal, medial, and apical levels throughout all samples. L, lateral; A, anterior; P, posterior; S, septal.
Segment scores are colored-coded from green to red: green = normal, yellow = hypokinesia, orange = akinesia, and red = dyskinesia or aneurysm. (F)
Representative SHG (white) and MPEF (green) microscopy images of transverse cardiac sections at 28 days post-MI. Scale bar, 500 mm. Magnified views
of boxed areas within the infarct are shown in the lower panels. Scale bar, 100 mm. Asterisks mark the epicardium. (G) Percentage SHG, skewness, and
kurtosis in infarcts at 28 days post-MI. Data are means ± SEM of 5–7 mice per genotype. Unpaired t-test.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Source data 1. Mj-restricted MT1-MMP deficiency attenuates LV dysfunction and dilation and reduces collagen deposition after MI.
Figure supplement 1. Isolation of cardiac Mjs after MI.
Figure supplement 2. Mouse model of Mj-specific MT1-MMP inactivation.
Figure supplement 2—source data 1. Mouse model of Mj-specific MT1-MMP inactivation.
Figure supplement 3. The inactivation of Mj MT1-MMP ameliorates cardiac dysfunction and reduces collagen deposition in a model of transient
ischemia.
Figure supplement 3—source data 1. The inactivation of Mj MT1-MMP ameliorates cardiac dysfunction and reduces collagen deposition in a model
of transient ischemia.
Figure supplement 4. MT1-MMP inactivation does not alter the Mj phenotype following MI.
Figure supplement 4—source data 1. MT1-MMP inactivation does not alter the Mj phenotype following MI.
Table 1. Mj MT1-MMP inactivation does not affect homeostatic cardiac function.
Echocardiography and electrocardiography comparisons between 10-week-old WT and MAC-Mmp14
KO mice. Data are means ± SEM of 10 mice per group. Unpaired t-test. BW, body weight; FS, fraction
shortening; HR, heart rate; HW, heart weight; LVEF, LV ejection fraction; LVIDd, LV end-diastolic inter-
nal diameter; LVIDs, LV end-systolic internal diameter; LVVold, LV end-diastolic volume; LVVols, LV
end-systolic volume.
WT MAC-Mmp14 KO
BW (g) 18.62 ± 2.00 19.53 ± 2.25
HW/BW (mg/g) 4.91 ± 0.28 4.94 ± 0.19
HR (beats/min) 462 ± 14 463 ± 17
PR (ms) 39.82 ± 1.18 37.70 ± 1.21
QRS (ms) 25.41 ± 1.06 26.18 ± 0.88
LVEF (%) 53.52 ± 1.72 53.14 ± 2.31
LVVols (mL) 21.53 ± 1.36 19.98 ± 1.60
LVVold (mL) 25.26 ± 0.96 22.22 ± 0.90
FS (%) 26.58 ± 0.89 26.33 ± 1.51
LVIDs (mm) 3.67 ± 0.06 3.54 ± 0.08
LVIDd (mm) 2.7 ± 0.06 2.62 ± 0.10
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respectively. SHG images of the infarct zone (IZ) revealed a highly directional and organized collagen
fibril morphology in the WT infarcted group, whereas a less-organized and sparse collagen structure
was observed in MAC-Mmp14 KO infarcted hearts (Figure 1F). Quantification of SHG signals
revealed a marked drop in fibrillary collagen density in MAC-Mmp14 KO infarcted hearts
(Figure 1G). In addition, the analysis of first-order features of collagen fibrils in SHG images showed
augmented skewness and kurtosis in MAC-Mmp14 KO mice, indicating thinner and underdeveloped,
disarrayed collagen fibers and thus lower tissue stiffness (Figure 1G).
Next, we investigated the effect of Mj-specific Mmp14 inactivation during the transient ischemia/
reperfusion (I/R) model of MI. Similar to the permanent occlusion model, transient ischemia impaired
LV function in both genotypes, but MAC-Mmp14 KO mice had a significantly higher LVEF and lower
LV end-systolic and end-diastolic internal diameters (LVIDs and LVIDd, respectively), indicating bet-
ter preserved LV function and prevention of LV dilation (Figure 1—figure supplement 3A). More-
over, SHG imaging analysis after I/R revealed a weaker fibrotic response, with thinner and sparser
collagen fibers in MAC-Mmp14 KO hearts (Figure 1—figure supplement 3B–C).
These data indicate that Mj Mmp14-deficiency decreases collagen fiber deposition, producing a
smaller and underdeveloped fibrotic scar that results in relatively low LV dilation and ameliorated
systolic dysfunction after transient or permanent cardiac ischemia.
Mmp14 inactivation in Mjs does not influence their phenotype
We first investigated whether Mmp14 inactivation influenced the Mj activation program. We
assessed classical anti-inflammatory genes expressed by cardiac Mjs at day 7 post-MI
(Walter et al., 2018) and no differences were
found between phenotypes (Figure 1—figure
supplement 4A). In line with a previous study
(Walter et al., 2018), most classical pro-inflam-
matory genes (Il6, Nos2, Cox2, and Cxcl12) were
not expressed in Mjs at this stage, and the few
that were expressed (Ccl2 and Cd86) did not dif-
fer between genotypes (Figure 1—figure sup-
plement 4A). To further investigate the effect of
Mmp14 inactivation on Mj polarization, we acti-
vated BMDMs in vitro with lipopolysaccharide
(LPS) or interleukin 4 (IL4) and analyzed the
expression of M1- and M2-related genes,
respectively (Figure 1—figure supplement 4B).
No differences in Mj polarization were found
between WT and KO BMDMs, suggesting that
Mmp14 inactivation does not affect the Mj M1/
M2 activation spectrum.
Table 2. Mj MT1-MMP inactivation does not affect circulating bone marrow-derived populations.
Hematograms from 10-week-old WT and MAC-Mmp14 KO mice. Data are means ± SEM of eight
mice per group.
WT MAC-Mmp14 KO
% Cells (103)/mL % Cells (103)/mL
Neutrophils 9.50 ± 0.98 0.74 ± 0.11 11.01 ± 1.43 0.88 ± 0.13
Lymphocytes 86.75 ± 1.29 6.97 ± 1.00 84.79 ± 1.68 6.84 ± 0.54
Monocytes 0.89 ± 0.14 0.08 ± 0.02 1.20 ± 0.13 0.10 ± 0.01
Eosinophils 2.45 ± 0.44 0.21 ± 0.06 2.48 ± 0.51 0.20 ± 0.04
Basophils 0.41 ± 0.08 0.03 ± 0.01 0.53 ± 0.09 0.05 ± 0.01
Video 1. Parasternal 2D long axis echocardiography
view of WT (top) or MAC-Mmp14 KO (bottom) hearts
at baseline (Day 0, left) and at 28 days post-MI (right)
induced by LAD-ligation.
https://elifesciences.org/articles/57920#video1
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MAC-Mmp14 KO mice have a preserved microvasculature network and
better myocardial oxygenation after ischemic injury
Next, we evaluated confocal images of WT and MAC-Mmp14 KO 7-day-post-MI hearts stained for
CD31 (endothelial marker) and SMA (smooth muscle actin) with a fully automated 3D pipeline (Mate-
rials and methods), which allows reconstruction and quantification of the microvasculature
(Gkontra et al., 2018; Table 3). MAC-Mmp14 KO 7-day-post-MI hearts had a higher vascular vol-
ume density and more capillaries and ECs within the infarction than WT hearts (Figure 2A–B). Oxy-
gen diffusion from blood to tissue critically depends on the density and arrangement of the
microvascular bed. Accordingly, in MAC-Mmp14 KO hearts, we observed increased capillary density
and reduced intercapillary and diffusion distances, parameters proposed as indices of oxygen diffu-
sion (Gkontra et al., 2018), suggesting better oxygen diffusion in the infarcted myocardium
(Figure 2B). Next, we assessed hypoxia in the post LAD-ligation myocardium by carbonic anhydrase
IX (CA-IX) staining (Figure 2C), which revealed a smaller CA-IX+ area in the infarction of 7-day-post-
MI MAC-Mmp14 KO hearts than in WT counterparts (Figure 2C–D), confirming better-preserved tis-
sue oxygenation after MI. No hypoxia signal was found in the non-infarcted tissue (Figure 2—figure
supplement 1A–B). Although there were no between-genotype differences in arteriole (SMA+ ves-
sels) density, there was a trend toward thinner arteriole vessel walls at 7 days post-MI in MAC-
Mmp14 KO infarcted hearts (Figure 2—figure supplement 1C–D), suggesting amelioration of MI-
induced arterial hyperplasia (Krishnamurthy et al., 2009) in the absence of Mj MT1-MMP.
The inactivation of Mj MT1-MMP impairs active TGFb1 release from
the LAP-TGFb1 complex
To elucidate the mechanism by which Mj MT1-MMP regulates microvascular density and fibrosis,
we sought soluble factors whose release might be affected by MT1-MMP. Two independent proteo-
mics studies previously performed in our laboratory detected a 1.25- to 2-fold increase in TGFb1
content in the membrane-enriched subcellular fraction of Mmp14 KO BMDMs. The small latent com-
plex (SLC) consisting of latency associated peptide (LAP) and mature TGFb1 can be retained at the
cell surface through LAP binding to membrane receptors (e.g. integrin avb8) (Figure 3A). It has
been shown that MT1-MMP promotes TGFb1 activation via integrin avb8 at the cell surface
(Mu et al., 2002), and that TGFb1 modulates myocardial healing through effects on the fibrotic and
angiogenic responses (Frangogiannis, 2020).
To investigate the possible role of Mj-derived MT1-MMP in TGFb1 release after MI, we used
flow cytometry to measure latent TGFb1 (LAP-TGFb1 complex) on the surface of LPS-stimulated WT
and MAC-Mmp14 KO BMDMs (Figure 3A–C). KO Mjs had a higher content of LAP and TGFb1,
revealing significantly higher surface retention of LAP-TGFb1 than observed in WT Mjs (Figure 3B–
C). To validate this observation, we detected TGFb1 by immunoblot in the membrane and cytosolic
subcellular fractions and total cell lysates of LPS-stimulated WT and MAC-Mmp14 KO BMDMs
(Figure 3D). Latent TGFb1 (~50 kDa) consisting of LAP (35 kDa) covalently bound to the mature
TGFb1 (12.5 kDa) preferentially located in the membrane and was more abundant in Mmp14-defi-
cient Mjs (Figure 3C–D). In line with the reported role of MT1-MMP in the posttranslational proc-
essing of pro-TGFb1, we found no difference in Tgfb1 transcript levels between WT and MAC-
Mmp14 KO BMDMs (Figure 3E).
Next, we queried whether impaired processing of LAP-TGFb1 complex by Mmp14-deficient Mjs
affects the secretion of active TGFb1. Since active TGFb1 has an estimated half-life of 2–3 min, and
only 2–5% of total TGFb1 is thought to be activated at any given time (Lawrence, 2001), we mea-
sured bioactive TGFb1 using a standardized luciferase assay (Materials and methods). Responsive-
ness of the luciferase construct to TGFb1 was confirmed by treating transfected HEK293 cells with
TGFb1 (2.94 ± 0.06 fold-increase in arbitrary luciferase units (ALU) with respect to the control). Lucif-
erase activity was then assessed in transfected HEK293 cells cultured in the presence or absence of
LPS-stimulated BMDMs for 24 hr (Figure 3F). HEK293 co-culture with WT BMDMs produced abun-
dant levels of active TGFb1, whereas active TGFb1 was undetectable after co-culture with MAC-
Mmp14 KO BMDMs (Figure 3F). TGFb1 levels in MAC-Mmp14 KO BMDMs were restored by trans-
duction with full-length (FL) MT1-MMP but not with a catalytic mutant (E240A), demonstrating that
MT1-MMP-dependent TGFb1 activation requires MT1-MMP catalytic activity (Figure 3G).
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Table 3. Quantitative analysis of microvasculature parameters in infarcted cardiac tissue from WT
and MAC-Mmp14 KO mice on day 7 after MI.
Capillaries correspond to CD31+SMA- vessels of diameter <3 mm. Data are means ± SEM of 5–6 mice
per genotype. Unpaired t-test. Significant differences are indicated as *p<0.05.
Minkowski-based metrics WT MAC-Mmp14 KO
Vascular volume density (%) 12.65 ± 0.36 13.26 ± 0.34 *
Vascular surface area density ( 10 3) (mm2/mm3) 21.24 ± 2.5 23.13 ± 1.92
Graph-based metrics
Vascular segment length (mm) 6.97 ± 0.74 6.2 ± 0.18
Vascular segment surface (mm2) 36.41 ± 5.52 29.5 ± 1.6
Vascular segment volume (mm3) 17 ± 3.8 12.54 ± 1.53
Tortuosity (mm/mm) 1.61 ± 0.02 1.61 ± 0.03
Vascular segments ( 105)a 4.12 ± 0.68 5.48 ± 0.53
Vascular segmentsb 144.17 ± 14.15 158.27 ± 2.31
Vessels of diameter <= 3 (mm) (%) 95.48 ± 2.55 96.97 ± 1.85 *
Vessels of diameter between 3 and 6 (mm) (%) 4.51 ± 2.52 3.03 ± 1.85
Vessels of diameter > 6 (mm) (%) 0.012 ± 0.001 0.028 ± 0.001
Vessels of diameter <= 3 (mm) ( 105)a 3.97 ± 0.71 5.33 ± 0.59 *
Vessels of diameter between 3 and 6 (mm) ( 105)a 0.16 ± 0.06 0.15 ± 0.09
Vessels of diameter > 6 (mm)a 32.81 ± 0.0001 73.36 ± 0.0001
Branching nodes ( 104)a 22.39 ± 4.28 30.43 ± 2.51
Blind-ends/sprouts ( 104)a 6.06 ± 0.92 7.93 ± 1.2
Branching nodesb 77.38 ± 9.59 87.31 ± 2.14
Blind-ends/sproutsb 24.09 ± 4.07 25.9 ± 1.66
SMA-related metrics
Vessels covered with SMA (%) 47.2 ± 17.67 53.54 ± 12
SMA+ layer thikness (mm) 2.98 ± 0.76 2.72 ± 0.43
Damage index 0.21 ± 0.11 0.19 ± 0.09
Myofibroblasts ( 104)a 2.51 ± 1.18 2.05 ± 0.64
Myofibroblastsb 8.9 ± 3.8 5.97 ± 1.47
Myofibroblasts ( 105)d 19.1 ± 10 15.3 ± 4.7
SMA+ perivascular cells ( 104)a 4.74 ± 2.36 5.25 ± 1.59
SMA+ perivascular cellsb 16.16 ± 7.31 15.48 ± 3.65
SMA+ perivascular cells ( 105)d 36.3 ± 19.3 38.9 ± 10.8
Efficiency in oxygen diffusion
Maximal extravascular distance (mm) 51.47 ± 10.83 45.47 ± 7.11
Median extravascular distance (mm) 14.28 ± 2.64 13 ± 1.38
Capillary densityc 1201 ± 298.12 1720 ± 368.61 *
Intercapillary distance 8.09 ± 0.51 7.31 ± 0.27 *
Diffusion distance 10.84 ± 0.51 9.76 ± 0.49 *
Additional cell-related metrics
Endothelial cells ( 104)a 6.2 ± 1.05 7.91 ± 1.21
Endothelial cellsb 22.45 ± 3.91 23.16 ± 1.34
Endothelial cells ( 105)d 46.6 ± 8.1 58.8 ± 7.7 *
a per mm3 of tissue,b per mm vessel length,c per mm2 of tissue,d per mm3 vessel volume.
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Figure 2. MAC-Mmp14 KO mice have a preserved microvasculature network and better myocardial oxygenation after ischemic injury. (A)
Representative confocal microscopy images showing immunostaining for CD31 (green) and nuclei (blue) within the infarction in WT and MAC-Mmp14
KO hearts at 7 days post-MI. Scale bar, 50 mm. (B) Vasculature-related parameters within the infarction at 7 days post-MI. Data are means ± SEM of 5–6
mice per genotype. Unpaired t-test. (C) Representative confocal immunofluorescence microscopy images of CA-IX (red) in the infarcted region of WT
and MAC-Mmp14 KO hearts at 7 days post-MI. Nuclei are stained with DAPI (blue). Scale bar, 100 mm. (D) CA-IX+ area:total area ratio in the infarcted
zone. Data are means ± SEM of 7–8 mice per genotype. Unpaired t-test.
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Source data 1. MAC-Mmp14 KO mice have a preserved microvasculature network and better myocardial oxygenation after ischemic injury.
Figure supplement 1. Remodeling of cardiac vasculature in MAC-Mmp14 KO mice after MI.
Figure supplement 1—source data 1. Remodeling of cardiac vasculature in MAC-Mmp14 KO mice after MI.
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Figure 3. Mj-inactivation of MT1-MMP impairs active TGFb1 release from LAP-TGFb1 complex. (A) Scheme of LAP-TGFb1 complex retention in the cell
surface through LAP-binding to membrane receptors. (B) Representative flow cytometry histogram plots of LAP and TGFb1 staining in LPS-activated
WT and MAC-Mmp14 KO BMDMs. (C) Standardized mean fluorescence intensity (MFI) of LAP and TGFb1 in experiments as in B. Data are means ±
SEM of seven mice per group. Unpaired t-test. (D) Western blot of transferrin receptor (TfR), a-tubulin, and LAP-TGFb1 complex in membrane fraction
(Mb), cytosolic fraction (C), and total lysate (T) from LPS-activated WT and MAC-Mmp14 KO BMDMs. (E) Quantification of LAP-TGFb1 complex in the
membrane fraction. Data are means ± SEM of 6–7 mice per genotype. Unpaired t-test. (F) Tgfb1 mRNA expression in LPS-activated WT and MAC-
Mmp14 KO BMDMs. Data are means ± SEM of five mice per genotype. Unpaired t-test. (G) Arbitrary luciferase units (ALU) in HEK293 cells co-cultured
with or without LPS-activated WT or MAC-Mmp14 KO BMDMs. Control corresponds to transfected HEK293 cells cultured alone. Data are means ± SEM
of a representative experiment of three performed with four technical replicates per condition. One-way ANOVA followed by Tukey’s multiple
comparisons test. (G) ALU in HEK293 cells co-cultured with or without conditioned media from LPS-activated MAC-Mmp14 KO BMDMs transduced with
mock lentivirus (GFP), or lentivirus containing full-length MT1-MMP (FL) or catalytic MT1-MMP mutant (E240A). Control corresponds to transfected
HEK293 cells cultured alone. Data are means ± SEM of a representative experiment of three performed with three technical replicates per condition.
One-way ANOVA followed by Tukey’s multiple comparisons test.
The online version of this article includes the following source data for figure 3:
Source data 1. Mj-inactivation of MT1-MMP impairs active TGFb1 release from the LAP-TGFb1 complex.
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The inactivation of Mj MT1-MMP reduces TGFb1-pSMAD2 signaling in
cardiac ECs, MyoFBs, and VSMCs after MI
We explored if the defective release of active TGFb1 by Mmp14-deficient Mjs could affect TGFb1-
mediated SMAD2/3 in the myocardium. We quantified phosphorylated SMAD2 (pSMAD2) in Mjs,
ECs, and myofibroblasts (MyoFBs) by flow cytometry in 7-day-post-MI hearts (Figure 4A–B). Mjs
were defined as CD45+CD11b+F4/80+ cells, and ECs as CD45-CD31+ cells (Figure 4A). Cardiac FBs
convert to MyoFBs with injury to mediate healing after MI and platelet-derived growth factor recep-
tor b (PDGFRb) induction is an early feature of MyoFB activation (Henderson et al., 2013). In line
with our previous papers (Gkontra et al., 2018; Żak et al., 2019), histological examination revealed
that PDGFRb indeed labels two distinct cell subsets in the infarcted myocardium: (i) PDGFRb+ cells
around vessels (pericytes and vascular smooth muscle cells (VSMCs)), and (ii) non-perivascular
PDGFRb+ cells (MyoFBs) (Figure 4—figure supplement 1). We, therefore, identified MyoFBs and
VSMCs as CD45-CD31-PDGFRb+ cells (Figure 4A). FACS of CD45-CD31-PDGFRb+ cells followed by
qPCR analysis confirmed the expression of MyoFB markers such as Tagln, Col1a1, Col1a2, and
Col1a3 (Figure 5—figure supplement 1A–B). There was no between-genotype difference in
pSMAD2 abundance in Mjs; however, pSMAD2 was significantly less abundant in ECs and MyoFBs/
VSMCs from MAC-Mmp14 KO hearts (Figure 4B–C), suggesting that lack of Mj MT1-MMP impairs
paracrine TGFb1-pSMAD2 signaling in ECs and MyoFBs/VSMCs. To distinguish between pSMAD2 in
MyoFBs (non-vascular-related SMA+ cells) and VSMCs (vascular-related SMA+ cells), we performed
confocal imaging analysis at 7 days post-MI which revealed that pSMAD2-positive MyoFBs and
VSMCs were both less abundant in MAC-Mmp14 KO hearts than in WT hearts (Figure 4D–E).
We also investigated the possible effect on cardiac FBs and CMs of reduced TGFb1 release by
Mmp14-deficient Mjs. qPCR analysis of cardiac FBs and CMs after culture with supernatants from
LPS-activated WT or MAC-Mmp14 KO BMDMs revealed no changes except for the direct TGFb1
gene target Serpine1, whose expression was significantly higher in FBs treated with conditioned
medium from WT BMDMs (Figure 4—figure supplement 2A). This result is consistent with the
higher production of active TGFb1 by WT BMDMs than by MAC-Mmp14 KO BMDMs (Figure 3G)
and the higher abundance of MyoFBs in KO hearts, suggesting a role for MT1-MMP in FB activation
to MyoFBs.
Mj-derived MT1-MMP induces EndMT after MI
We found that Mj MT1-MMP inactivation altered the cellular composition of the infarcted myocar-
dium, with MAC-Mmp14 KO mice showing fewer Mjs, indicating a less inflammatory state; more
ECs, in line with the microvasculature image analysis data; and fewer MyoFBs, in agreement with the
reduced fibrotic response (Figure 5A–B). Additionally, we detected an intermediary population of
cells with mild levels of both CD31 (endothelial marker) and PDGFRb (mesenchymal marker)
(Figure 5A). This population is suggestive of transitioning cells undergoing endothelial to mesenchy-
mal transition (EndMT) (Aisagbonhi et al., 2011). To confirm the occurrence of EndMT in the con-
text of MI, we performed lineage tracing experiments in Cdh5-CreERT2 R26Tomato control and
infarcted mice and asked whether we could find endothelial-cell derived Tomato+ cells within the
MyoFB compartment using flow cytometry (Figure 5—figure supplement 2A–E). We detected an
increase in Tomato+PDGFRb+ cells in 7-day-post-MI hearts (Figure 5—figure supplement 2D,E),
confirming that EndMT is triggered upon MI as previously reported (Aisagbonhi et al., 2011). We
confirmed the transitioning phenotype of CD31+PDGFRb+ cells by qPCR and observed the loss of
endothelial markers (i.e. Pecam, Cdh5, Kdr, Tie2, Col4a2), the acquisition of mesenchymal genes
(i.e. Cdh2, Tagln, Col1a1, Col1a2, Col3a1), and the upregulation of EndMT-mediating transcriptional
factors (i.e. Zeb2 and Snai1) (Figure 5—figure supplement 1A–B). Interestingly, these cells were
less abundant in MAC-Mmp14 KO hearts (Figure 5A–B), suggesting that EndMT is impaired in the
absence of Mj MT1-MMP. We confirmed the results obtained with PDGFRb staining by the comple-
mentary staining for MEFSK4 (Figure 5—figure supplement 3A,B), another marker for cardiac FB
lineage (Pinto et al., 2016).
TGFb is considered the master mediator of EndMT, in a SMAD-dependent manner (Frangogian-
nis, 2020). We found by immunofluorescence triple-positive cells for the endothelial nuclear marker
ERG, the mesenchymal marker SMA and pSMAD2, reflecting the transition of endothelial cells
towards a mesenchymal phenotype via SMAD2 activation in the infarcted cardiac tissue (Figure 5—
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Figure 4. The inactivation of Mj MT1-MMP reduces TGFb1-pSMAD2 signaling in cardiac ECs, MyoFBs, and VSMCs after MI. (A) Gating strategy used
to assess pSMAD2 signaling in ECs, MyoFBs/VSMCs, and Mjs. (B) Representative flow cytometry histogram plots of pSMAD2 staining in the indicated
cells from 7-day-post-MI hearts. (C) Standardized MFI of pSMAD2 in experiments as in B. Data are means ± SEM of 7–8 mice per genotype. Unpaired t-
test. (D) Representative immunofluorescence staining of CD31 (green), SMA (red), and pSMAD2 (white) in infarcted cardiac tissue from WT mice (top)
Figure 4 continued on next page
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Figure 4 continued
and MAC-Mmp14 KO mice (bottom) at 7 days post-MI. Nuclei are stained with DAPI (blue). Red and yellow arrowheads point to pSMAD2+ MyoFBs and
pSMAD2+ VSMCs, respectively. Scale bar, 50 mm. (E) Percentages of pSMAD2+ MyoFBs and pSMAD2+ VSMCs within the total MyoFB or VSMC
populations, respectively in the infarcted zone. Data are means ± SEM of six mice per genotype. Unpaired t-test.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. The inactivation of Mj MT1-MMP reduces TGFb1-pSMAD2 signaling in cardiac ECs, MyoFBs, and VSMCs after MI.
Figure supplement 1. PDGFRb is expressed by cardiac MyoFBs and VSMCs.
Figure supplement 2. Effect of WT or MAC-Mmp14 KO Mjs on FBs and CMs.
Figure supplement 2—source data 1. Effect of WT or MAC-Mmp14 KO Mjs on FBs and CMs.
Figure 5. The inactivation of Mj MT1-MMP alters myocardial cellular composition after MI. (A) Flow cytometry gating strategy used to identify and
quantify cardiac ECs, MyoFBs, cells undergoing EndMT, and Mjs in WT mice (left) and MAC-Mmp14 KO mice (right) on day 7 after MI. (B)
Quantification of Mjs, ECs, MyoFBs, and cells undergoing EndMT in cardiac tissue 7 days after MI. Data are means ± SEM of at least 11 mice per
genotype. Unpaired t-test.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. The inactivation of Mj MT1-MMP alters myocardial cellular composition after MI.
Figure supplement 1. Endothelial-to-mesenchymal gene signature of CD31+PDGFRb+ cells.
Figure supplement 1—source data 1. Endothelial-to-mesenchymal gene signature of CD31+PDGFRb+ cells.
Figure supplement 2. Lineage tracing of endothelial derived-mesenchymal cells.
Figure supplement 3. The inactivation of Mj MT1-MMP attenuates post-MI EndMT.
Figure supplement 3—source data 1. The inactivation of Mj MT1-MMP attenuates post-MI EndMT.
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figure supplement 3C–D). We, therefore, studied the effect on post-MI EndMT of the impaired
TGFb1 production by Mmp14-deficient Mjs, and the associated reduction in paracrine pSMAD2 sig-
naling in ECs. For that, we co-cultured purified mouse aortic endothelial cells (MAECs) with LPS-acti-
vated WT or MAC-Mmp14 KO BMDMs (Figure 6—figure supplement 1). The immunofluorescence
analysis with the endothelial marker CD31 and the mesenchymal marker SMA revealed morphologi-
cal changes in MAECs after co-culture with WT BMDMs, with cells progressively losing their cobble-
stone appearance and adopting a dispersed, spindle-shaped morphology (Figure 6—figure
supplement 1A). Moreover, MAECs co-cultured with WT BMDMs significantly decreased CD31
expression and acquired SMA expression, indicating the acquisition of molecular traits of a mesen-
chymal phenotype (Figure 6—figure supplement 1A–B). This phenotype was similar to the effects
of recombinant TGFb1 stimulation (Figure 6—figure supplement 1A–B). By contrast, co-culture of
MAECs with MAC-Mmp14 KO BMDMs led neither to the loss of endothelial features nor to the
acquisition of mesenchymal markers (Figure 6—figure supplement 1A–B). Treatment of MAEC-
BMDM co-cultures with a neutralizing anti-TGFb1 antibody blocked EndMT, demonstrating that Mjs
induced EndMT via MT1-MMP/TGFb1 (Figure 6—figure supplement 1C–D). Altered expression of
endothelial and mesenchymal markers in the co-cultures was confirmed by qPCR. In accordance with
the immunofluorescence data, the co-culture of MAECs with WT BMDMs caused the downregulation
of EC-related genes (Pecam, Kdr, and Col4a2) and the upregulation of mesenchymal genes (Tagln
and Acta2) and the direct TGFb1 target Serpine1 (Pai1). A similar phenotype was induced by TGFb1-
treatment. By contrast, these changes toward a mesenchymal phenotype in MAECs were not trig-
gered by co-culture with MAC-Mmp14 KO BMDMs (Figure 6—figure supplement 2).
To confirm Mj MT1-MMP-dependent induction of EndMT in vivo following MI, we first investi-
gated TGFb1 processing in cardiac Mjs. LAP and TGFb1 were both significantly increased on the
surface of MAC-Mmp14 KO Mjs after MI, indicating the retention of latent TGFb1 (Figure 6A). We
then sorted cardiac Mjs from 7-day-post-MI WT and MAC-Mmp14 KO hearts (Figure 1—figure
supplement 1A–B) and co-cultured them with luciferase-transfected HEK293 cells. As with BMDMs,
post-MI WT cardiac Mjs produced detectable levels of active TGFb1, whereas the inactivation of
Mmp14 in Mjs abrogated TGFb1 activation (Figure 6B). In co-culture experiments, WT cardiac Mjs
induced EndMT in MAECs, downregulating CD31 expression, and increasing SMA expression. By
contrast, no transition to a mesenchymal phenotype was evident in MAECs co-cultured with
Mmp14-deficient cardiac Mjs (Figure 6C–D).
Discussion
MI results in loss of CMs, adverse structural remodeling, and LV dysfunction and dilation, eventually
causing heart failure. Since appropriate cardiac repair requires a balanced inflammatory response to
avoid adverse cardiac remodeling after MI, Mjs have emerged as likely candidates for investigation
and therapeutic intervention. Our results show that post-MI Mjs have heightened expression of
Mmp14 as well as its substrates Mmp2 and Col1a1, in line with a role in tissue remodeling and colla-
gen deposition (O’Rourke et al., 2019). Although ECM remodeling and granulation tissue formation
are prerequisites for tissue repair, excessive MMP activity after MI and subsequent ECM turnover
can result in adverse remodeling and worsened cardiac dysfunction (Spinale et al., 2010). Therefore,
we hypothesized that Mj-specific inactivation of MT1-MMP might limit adverse remodeling and LV
dilation and dysfunction after MI.
Although MAC-Mmp14 KO mice are phenotypically normal under homeostatic conditions, these
animals were protected when challenged by acute MI. MAC-Mmp14 KO mice had smaller infarcts
and better LV contractility after MI than WT mice, as well as significantly improved preservation of
systolic function and LV structure. A detrimental role of MT1-MMP in post-MI cardiac remodeling
has been identified using mouse infarct models, leading to worsening cardiac function and reduced
survival (Koenig et al., 2012; Spinale et al., 2010; Zavadzkas et al., 2011). These studies attributed
this detrimental role to MT1-MMP collagenase activity in FBs, disregarding its actions in Mjs
(Koenig et al., 2012). Our data obtained with the MAC-Mmp14 KO model are the first demonstrat-
ing the beneficial effect of Mj-specific MT1-MMP inactivation in preventing adverse LV remodeling
after MI. This effect is likely caused by the lower myocardial fibrosis, allowing the heart to work at
less of a mechanical disadvantage, and better oxygenation of the infarcted myocardium due to the
preservation of the microvasculature network.
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Figure 6. Cardiac Mjs induce post-MI EndMT through MT1-MMP-mediated TGFb1 activation. (A) Standardized MFI of LAP and TGFb1 staining in WT
and MAC-Mmp14 KO cardiac Mjs on day 7 after MI. Data are means ± SEM of 6–7 mice per group. Unpaired t-test. (B) Luciferase activity (ALU) in
transfected HEK293 cells co-cultured with Mjs from 7-day-post-MI WT or MAC-Mmp14 KO hearts. Data are means ± SEM of three independent
experiments performed with four technical replicates per condition. One-way ANOVA followed by Tukey’s multiple comparisons test. (C)
Representative immunofluorescence staining of CD31 (green) and SMA (red) in in vitro co-cultures of MAECs and cardiac Mjs from WT or MAC-
Mmp14 KO 7-day-post-MI hearts. Nuclei are stained with DAPI (blue). Scale bar, 100 mm (D) CD31+ area (mm2) and SMA+ area (mm2) in the different
conditions. Data are means ± SEM of a representative experiment of three performed with three technical replicates per condition. Unpaired t-test.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. Cardiac Mjs induce post-MI EndMT through MT1-MMP-mediated TGFb1 activation.
Figure supplement 1. Mjs induce EndMT in vitro via MT1-MMP/TGFb1.
Figure supplement 1—source data 1. Mjs induce EndMT in vitro via MT1-MMP/TGFb1.
Figure supplement 2. MT1-MMP is required for in vitro Mj induction of EndMT.
Figure supplement 2—source data 1. MT1-MMP is required for in vitro Mj induction of EndMT.
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Loss of collagenase activity in MAC-Mmp14 KO mice might be expected to lead to a dense scar.
However, in addition to its collagenolytic activity (Ohuchi et al., 1997), MT1-MMP proteolytically
processes a diverse range of biologically active signaling molecules (Koziol et al., 2012); stimulation
of collagen synthetic pathways by these molecules would explain the observed phenotype of post-
MI MAC-Mmp14 KO mice. Pro-TGFb has been recognized as a target for MT1-MMP–mediated
Figure 7. Mj-inactivation of MT1-MMP preserves cardiac function after MI by impairing TGFb1-mediated EndMT. MI triggers MT1-MMP production by
Mjs, contributing to the release of active TGFb1 from SLC (LAP-TGFb1) to the myocardium. Active TGFb1 signals acting on ECs promote EndMT,
contributing to adverse tissue remodeling. When Mj MT1-MMP is absent, latent TGFb1 accumulates, and the availability of active TGFb1 in the
myocardium decreases. In this scenario, the impairment of Mj-mediated EndMT results in enhanced angiogenesis and reduced fibrosis, limiting LV
remodeling, and preserving cardiac function.
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cleavage in several contexts (Koziol et al., 2012; Mu et al., 2002). Our results provide evidence for
MT1-MMP-mediated activation of latent LAP-TGFb1 complex in cardiac Mjs after MI. Dampened
processing and release of active TGFb1 in MAC-Mmp14 KO mice was associated with a decrease in
SMAD2-mediated signaling in the infarcted myocardium, providing a mechanism for the reduced
pro-fibrotic response and preservation of the microvasculature network. Previous studies identified
MT1-MMP as an inducer of fibrosis through its cleavage of latent-transforming growth factor beta-
binding protein 1 (LTBP1) and activation of TGFb-mediated SMAD2/3 signaling in the infarcted myo-
cardium (Spinale et al., 2010; Zavadzkas et al., 2011). TGFb1 is the main driver of FB differentia-
tion to MyoFBs (van den Borne et al., 2010); our results, showing reduced MyoFBs numbers in
MAC-Mmp14 KO hearts and depressed Serpine1 expression by FBs treated with MAC-Mmp14 KO
Mjs, suggest that MT1-MMP plays a role in MyoFB activation via TGFb1. Suppressed TGFb1 pro-
duction may also underlie the preservation of the microvasculature network in MAC-Mmp14 KO
mice, through the loss of TGFb1 angiostatic effects (Arnold et al., 2014; Imaizumi et al., 2010).
However, the reduced release of TGFb1 by MAC-Mmp14 KO Mjs did not appear to affect, auto-
crine or paracrine, the Mj polarization phenotype or the gene signature of CM and FB (other than
Serpine1). Further studies will be needed to fully define these processes.
TGFb-mediated EndMT has been identified during cardiac fibrosis (Zeisberg et al., 2007) and
contributes to collagen matrix deposition and disease. The concomitant loss of functional ECs may
also lead to capillary rarefaction, thus causing tissue ischemia, a potent driver of fibrosis. EndMT is
essential for cardiac valve formation and vascular development in embryogenic stages as well as in
the pathogenesis of diverse cardiovascular disorders, such as congenital heart disease
(Hofmann et al., 2012; Xu et al., 2015). The contribution of EndMT to cardiac fibrosis remains how-
ever a matter of debate, which depends on the nature of the cardiovascular injury and the extent of
the fibrosis (Aisagbonhi et al., 2011; Evrard et al., 2016; Kanisicak et al., 2016; Moore-
Morris et al., 2014; Zeisberg et al., 2007). For example, EndMT is minimal in pressure overload or
I/R models, where the intensity of inflammatory and fibrotic responses is much lower than after acute
ischemic injury (Moore-Morris et al., 2014; Xia et al., 2009). Besides, the tools employed for
assessing EndMT present several limitations; for instance, immunofluorescence techniques are not
sensible enough to reliably detect and quantify dim levels of protein expression that characterize
cells under the EndMT transition. Lineage tracing experiments are a preferable approach, although
the specificity of the driver represents also a caveat (Kovacic et al., 2019; Li et al., 2018; Piera-
Velazquez and Jimenez, 2019).
Our results using flow cytometry, a technique that allowed us to finely track shifts in the expres-
sion of markers associated with EndMT, showed changes in ECs, ‘transitioning cells’, and MyoFBs
that demonstrate a role of Mj-derived MT1-MMP in TGFb1-mediated EndMT after MI. This conclu-
sion is supported by the identification of ERG+SMA+ cells with active SMAD2 signaling within the
infarct and by the results with in vitro experiments showing that addition of neutralizing anti-TGFb1
antibody to EC-Mj co-cultures abolished EndMT. Our findings are in line with the role of MT1-MMP
as an activator of epithelial to mesenchymal transition (EMT) in other pathophysiological contexts
such as development, cancer, and lung fibrosis (Garmon et al., 2018; Nguyen et al., 2016;
Xiong et al., 2017). Interestingly, a recent scRNAseq study carried out on healthy and post-infarcted
hearts identified a subset of post-MI Mjs with a HIF1a-dependent signature, which specifically upre-
gulated Mmp14 expression (Dick et al., 2019). The Mmp14 expression in these cells converges with
a hypoxia-driven program, which represents a well-known stimulus for EndMT (Evrard et al., 2016),
further supporting the implication of Mmp14-expressing post-MI Mjs in EndMT. Moreover, Mjs
have recently been reported as inducers of EndMT in atherosclerosis (Helmke et al., 2019).
Based on our discoveries, we propose that MT1-MMP mediated TGFb1-activation in Mjs after
ischemic injury contributes, among other possible TGFb-regulated processes, to local EndMT and
the generation of MyoFBs during granulation tissue formation. These cells might then take part in
fibrosis, giving rise to a dense fibrotic scar that compromises LV cardiac function after MI. Restrain-
ing Mj-mediated TGFb1 activation by MT1-MMP thus limits EndMT, favoring preservation of cardiac
microvasculature, improving myocardial blood flow, and reducing tissue hypoxia and fibrotic scarring
(Figure 7). These alterations in MAC-Mmp14 KO mice limited LV dilation and dysfunction and sug-
gest novel approaches to the promotion of cardiac recovery after MI. Therapeutic strategies would
consist of manipulating Mj MT1-MMP production in order to control EndMT and likely other profi-
brotic TFGb effects, thus promoting angiogenesis and moderating scar formation. Interestingly, in
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an experimental rat model of MI, treatment with menstrual-blood–derived mesenchymal stem cells
has been shown to protect endothelial function, reduce infarct size, decrease cardiac fibrosis, and
downregulate TGFb1/SMAD signaling, all through the comprehensive inhibition of EndMT
(Zhang et al., 2013). Following this rationale, previous studies have pointed to the beneficial effect
of pharmacological inhibition of MMPs on post-MI cardiac remodeling; however,
the implementation of clinically relevant therapies has proved difficult (Creemers et al., 2001;
Hudson et al., 2006; Yabluchanskiy et al., 2013). A recent study reported that selective MT1-MMP
inhibition rescued tissue damage and mortality in influenza-infected mice, demonstrating the poten-
tial of specific MT1-MMP inhibitors to ameliorate the detrimental effects of this protease on tissue
remodeling (Talmi-Frank et al., 2016). Controlling dysregulated myocardial MT1-MMP activity in
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Recombinant DNA reagent p3TP-lux Wrana et al., 1992 RRID:Addgene_11767 Dr. Carmelo Bernabeu
Sequence-based reagent qPCR primers This paper Supplement file 1
Peptide, recombinant protein Human TFGb1 Peprotech 100–21
Peptide, recombinant protein IL4 Peprotech 214–14
Peptide, recombinant protein Murine M-CSF Peprotech 315–02
Chemical compound, drug LPS Sigma L2654
Chemical compound, drug Tamoxifen Sigma T5648
Chemical compound, drug Collagenase type IV Sigma C5138
Chemical compound, drug Collagenase type I Worthington LS004194
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Chemical compound, drug Collagenase type II Worthington LS004174
Chemical compound, drug Porcine pancreatin Sigma P3292
Chemical compound, drug RBC Lysis buffer solution eBioscience 00-4333-57
Chemical compound, drug Passive Lysis 5 Buffer Promega E1941
Chemical compound, drug TRIzol Reagent Thermofisher 15596026
Chemical compound, drug Fluoromont-G Southern Biotech 0100–01
Commercial assay or kit Dynabeads Sheep
Anti-Rat IgG
Thermofisher 11035
Commercial assay, kit Foxp3/Transcription
Factor Staining Buffer Set
eBioscience 00-5523-00
Commercial assay, kit High Capacity cDNA
Reverse Transcription Kit
Applied Biosystems 4368814
Commercial assay, kit Bradford Assay Bio-Rad 5000001
Commercial assay, kit Luciferase Assay System Promega PR-E1500
Software, algorithm Vevo 2100 Visual Sonics RRID:SCR_015816
Software, algorithm Fiji fiji.sc RRID:SCR_002285
Software, algorithm GraphPad Prism www.graphpad.com RRID:SCR_002798
Software, algorithm FlowJo www.flowjo.com RRID:SCR_008520
Software, algorithm qBASE+ (Biogazelle) www.qbaseplus.com RRID:SCR_003370
Software, algorithm NDP.view2 Hamamatsu Photonics
Software, algorithm Zen2 Zeiss RRID:SCR_013672
Software, algorithm 3D fully automated
image analysis
Gkontra et al., 2018
Mice
All the animals used in this study were on the C57BL/6 background. Experiments were performed in
8- to 12-week-old both male and female mice, unless otherwise indicated, kept in a specific patho-
gen-free (SPF) facility at Centro Nacional de Investigaciones Cardiovasculares (CNIC) under a 12 hr
light/dark cycle (lights on from 07:00 to 19:00 hr), with water and chow available ad libitum. All ani-
mal procedures were conducted in accordance with EU Directive 86/609/EEC and approved by the
Animal Subjects Committee of the Instituto de Salud Carlos III (Madrid, Spain) and Madrid Commu-
nity Organs in the PROEX 188/26. Animals used in this study were C57BL/6 mice (Charles River),
Lyz2-Cre mice (Clausen et al., 1999), and Mmp14f/f mice (Gutiérrez-Fernández et al., 2015). Lyz2-
Cre+/Mmp14f/f mice (MAC-Mmp14 KO) lack Mmp14 in Mjs; while Lyz2-Cre-/Mmp14f/f littermates
were used as WT controls. For endothelial lineage tracing experiments, we used Cdh5-CreERT2 mice
(Sörensen et al., 2009) crossed with R26TdTomato mice (Madisen et al., 2010). Tamoxifen (Sigma-
Aldrich) was dissolved in corn oil (15 mg / mL) and injected intraperitoneally (0.15 mg tamoxifen/g
mouse body weight) 5 days before LAD-ligation surgery.
Mouse models of MI
Left anterior descending coronary artery ligation (LAD-ligation)
Permanent ligation of the left anterior descendent (LAD) coronary artery was performed as previ-
ously described (Kolk et al., 2009). Briefly, mice were anesthetized with sevoflurane (5% for induc-
tion, 2–3% for maintenance), and intubated using a 24-gauge intravenous catheter with a blunt end.
Mice were artificially ventilated with a mixture of O2 and air (1:1 [vol/vol]) using a rodent ventilator
(minivent 845) with 160 strokes/min in a total volume of 250 mL. The mouse was placed on heating
pad to maintain body temperature at 37˚C. A thoracotomy was performed through the fourth left
intercostal space, the pericardium was opened, and the heart was exposed. The proximal LAD coro-
nary artery was permanently ligated with a 7/0 silk suture (Lorca Marı́n). The thorax and the skin
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incision were closed with 6/0 silk sutures (Lorca Marı́n) and buprenorphine (0.01 mg/kg, Buprex,
Merck) was given for pain relief. Mice were sacrificed by CO2 inhalation 3, 7, or 28 days post-MI. Ani-
mals not subjected to surgery were included as the physiological condition (day 0).
Ischemia-reperfusion (I/R)
I/R protocol was performed as previously described (Inserte et al., 2019), following the same anes-
thetic and thoracotomy protocol as in permanent LAD-ligation. Once the heart was exposed, the
LAD coronary artery was ligated approximately 1 mm below the edge of the left atrial appendage
with an 8/0 silk suture (EthiconEndo-surgery, OH, USA). Regional ischemia was verified by visual pal-
lor and QRS alterations within the first seconds of occlusion. After occlusion for 45 min, the suture
was loosened to start reperfusion. The thorax and the skin incision were closed with 6/0 silk sutures
(Lab Arago, Spain) and buprenorphine (0.01 mg/kg, Buprex, Merck) was given for pain relief. Mice
with lack of ST-elevation during ischemia or lack of ST-recovery at reperfusion were excluded from
further evaluation. Mice were sacrificed by CO2 inhalation 21 days post-MI. Animals not subjected to
surgery were included as the physiological condition (day 0).
For the two models of MI, mice with less than two affected LV segments after the surgery in
terms of contractility were considered non-properly infarcted and excluded from the study.
Echocardiographic analysis
Transthoracic echocardiography was performed on mice subjected to LAD-ligation or I/R at basal, 1,
7, and 21 or 28 days post-surgery. Infarct size was monitored by echocardiography 1 day after sur-
gery to allow comparison of infarcts between genotypes. Shaved mice were anesthetized by inhala-
tion of isoflurane and oxygen (1.25% and 98.75%, respectively) and placed in a biofeedback
warming station that maintained core body temperature. Anesthesia depth was adjusted to maintain
heart rate between 450 and 550 beats per minute. Warm ultrasound gel was applied to the chest of
the animals, and echocardiography measurements were obtained using the VEVO 2100 high fre-
quency ultrasound system with a linear transducer MS400 18–38 MHz (Visual Sonics, Toronto, Can-
ada). Parasternal long- and short-axis views at three levels (base, middle, and apex) in two-
dimensional and M-mode were obtained as described previously (Cruz-Adalia et al., 2010). The LV
end-systolic and end-diastolic volume (LVVols and LVVold, respectively) were acquired from the par-
asternal two-dimensional long-axis view, and LV ejection fraction (LVEF) was calculated using the
area-length method (Ram et al., 2011). Wall thickness at the end of the systole and diastole was
measured from the M-mode short-axis view. The analysis was performed off-line by two blinded
echocardiography experts.
Regional kinetic abnormalities within the LV were assessed. LV wall motion score index (WMSI)
was calculated to assess global and regional cardiac function by a 12-based segment model, consid-
ering parasternal two-dimensional short and long-axis views at the three levels, as previously
described (Gallego-Colon et al., 2016). In each level, the LV was further divided into four segments
(anterior, lateral, posterior, and septal) and every segment was scored according to its severity in
terms of contraction as 1 (normal), 2 (hypokinesia), 3 (akinesia), 4 (dyskinesia or aneurysm). Infarct
size was estimated as the percentage of individual segments scored >1 (reflecting contractility
abnormalities) over the total of LV segments, and WMSI was defined as the ratio of the sum of the
score of every segment over the total number of segments evaluated.
Flow cytometry and cell sorting
Cardiac single-cell suspensions were obtained as previously described (Alonso-Herranz et al.,
2019). Briefly, mice were euthanized by CO2 fixation and immediately perfused by intracardiac injec-
tion of cold PBS. Right and left atria were removed and the whole ventricles were minced with fine
scissors and digested in collagenase IV 0.1% (528 U/mg Sigma) in PBS at 37˚C for 45 min under gen-
tle shaking. Cells were then filtered through nylon mesh of 100 mm (BD biosciences) to obtain a
homogeneous cell suspension and were subjected to red blood cell lysis with RBC Lysis buffer solu-
tion (eBioscience). Single-cell suspensions were Fc-blocked using anti-mouse CD16/CD32 antibody
(BD Pharmingen) 10 min at 4˚C in FACS buffer (PBS 2% FBS 5 mM EDTA). Antibodies were incu-
bated for 30 min at 4˚C in FACS buffer. Where appropriate, cells were further incubated with strep-
tavidin conjugates for 30 min at 4˚C. For nuclear pSMAD2 staining, cells were fixed and
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permeabilized using a commercial kit (Foxp3/Transcription Factor Staining Buffer Set, eBioscience).
Flow cytometry studies were performed in a BD FACSCantoTM II flow cytometer (BD BioSciences)
and analyzed with FlowJo Software (Tree Star). Cell sorting was performed with BD FACS-ARIATM II
cell sorter (BD Biosciences).
After pre-selection in side scatter (SSC) versus forward scatter (FSC) dot plot to exclude debris
and doublets, cardiac Mjs were identified as CD45+CD11b+F4/80+ cells, ECs as CD45-CD31+-
PDGFRb- cells, ‘transitioning’ cells as CD45-CD31lowPDGFRblow cells, and VSMCs and MyoFBs as
CD45-CD31-PDGFRb+ cells. Within the CD45+CD11b+ cells, the F4/80+Ly6Clow cardiac Mjs were
sorted at 0, 7, and 28 days post-MI, whereas F4/80+Ly6Chigh cardiac Mjs were purified for 3 days
post-MI.
Fluorescence minus one (FMO) controls were included during acquisition for gating analyses to
distinguish positive from negative staining cell populations. The standardized median fluorescence
intensity (MFI) of TGFb1, LAP, and pSMAD2 for each cardiac cell type was calculated as previously




Whereas medianpositive is the median intensity of the positive cell population, medianFMO is the
median intensity of the FMO, and SDFMO is the standard deviation of the intensity of the FMO.
RNA isolation and quantitative real-time PCR (qPCR)
Cells were lysed with TRIzol Reagent (Ambion) for RNA isolation. Total RNA was isolated from at
least three independent biological replicates, and RNA quality and quantity measured using the
NanoDrop ND100 (Thermo Scientific). Total RNA was reverse-transcribed to cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qPCR analysis was performed using
Sybr Green probes in the AB7900 FAST 384 Detection System (Applied Biosystems), according to
the manufacturer´s instructions. Gene expression values were normalized to the housekeeping genes
36b4 and Cyclophilin, and expressed as relative mRNA level. Data were analyzed by qBASE+ soft-
ware (Biogazelle) obtaining the Ct of the amplification products. Primer sequences are provided in
Supplementary file 1.
Histology and immunohistochemistry
For histological analysis, hearts were perfused with cold PBS, fixed in 4% PFA overnight, and embed-
ded in paraffin. Transverse sections (5 mm) were stained with hematoxylin-eosin (H and E) and Mas-
son trichrome stain according to standard procedures.
For immune-labeling of arterioles, samples were stained with anti-SMA, afterward with appropri-
ate HRP conjugated antibody, and finally revealed with 3,3’-diaminobenzidine (DAB) following stan-
dard protocols. Whole slide images were acquired with a digital slide scanner (Hamamatsu,
Nanozoomer-RS C110730) and then visualized, and exported to TIFF images using NDP.view2 soft-
ware (Hamamatsu Photonics).
Manual and automated quantifications were performed with Fiji Image J Software (NIH, https://
imagej.nih.gov/ij/). The infarct zone (IZ), and the remote zone (RZ) were defined on the basis of H
and E-stained sections. In particular, areas containing dying or dead CMs (picnotic or absent nuclei,
wavy fibers) or fibrotic areas were defined as IZ, whilst the RZ was considered the healthy LV free
wall. Measurements were performed on sections obtained from the midpoint of the infarct.
Multi-Photon microscopy and second harmonic generation imaging
Collagen fibers were visualized in H and E-stained heart sections with a Zeiss LSM 780 microscope
coupled to a Spectra-Physics Mai Tai DS [pulse <70 ps] laser, by second harmonic generation (SHG)
and multi-photon excitation fluorescence (MPEF) microscopy imaging technique (Abraham et al.,
2010). Optical sections were acquired every 3 mm (25 objective) and stitched using Zen 2 software
(Zeiss). The images were then stacked and flattened with Image J software to create maximum inten-
sity Z-projections. Collagen density was calculated using a simple threshold pixel counting method
within the IZ and expressed as the area fraction (% SHG). Skewness (asymmetry of pixel distribution)
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and kurtosis (gray-tone spread-out distribution) were assessed as indicative of fiber arrangement
(Mostaço-Guidolin et al., 2013).
Tissue immunofluorescence and confocal microscopy
Transverse paraffin sections (7 mm) of infarcted hearts were deparaffinized, rehydrated, and finally
washed in PBS 5 min twice. Antigen retrieval was performed by means of pH = 6 citrate buffer for
20 min in the microwave at maximum intensity. Afterward, sections were cooled down at room tem-
perature (RT) for 1 hr 30 min and then washed with PBS 5 min twice. Sections were blocked for 1 hr
at RT (0.3% Triton X-100, 5% goat serum, and 5% BSA in PBS) and primary antibodies were incu-
bated overnight at 4˚ C (0.3% Triton X-100, 2.5% goat serum, and 2.5% BSA in PBS). Next, sections
were washed with 0.1% Triton X-100 in PBS at RT for 10 min three times and secondary antibodies
and DAPI (1/5000) for nuclear staining were then incubated for 1 hr 30 min at RT (0.3% Triton X-100,
2.5% goat serum, and 2.5% BSA in PBS). After four washing steps with 0.1% Triton X-100 in PBS at
RT for 10 min plus 10 min more with PBS alone, slides were mounted with Fluoromont-G (Southern
Biotech). Images were acquired with a Nikon A1R confocal microscope with sections every 1.5 mm.
Three to four areas were acquired within the IZ (the two most distal edges and the center of the
infarcted area), and the other three to four within the RZ (LV free wall most distal to the infarct).
For the in vivo EndMT identification, transverse paraffin thick sections (14 mm) of 7 day-post-
infarcted hearts were sequentially stained. For sequential immunostaining, primary rabbit pSMAD2
was incubated overnight at 4˚C (0.3% Triton X-100, 2.5% goat serum, and 2.5% BSA in PBS). After
washing, goat anti-rabbit Alexa 488 was incubated 1 hr at RT (0.3% Triton X-100, 2.5% goat serum,
and 2.5% BSA in PBS). Sections were afterward thoroughly washed, and additional blocking was per-
formed with 0.3% Triton X-100, 5% rabbit serum, and 5% BSA in PBS 1 hr at RT. Directly labeled pri-
mary antibodies (mouse anti-SMA-Cy3 and rabbit anti-ERG-647) and DAPI were then incubated 1 hr
at RT. Finally, sections were washed and mounted as indicated before. Visual co-localization of the
three markers (ERG, SMA, and pSMAD2,) was performed with the orthogonal view plug-in of
ImageJ.
For CA-IX quantifications, the total area covered by the CA-IX signal in every image was normal-
ized by the total area, and this ratio was averaged in between individuals. For pSMAD2 quantifica-
tion in VSMCs and MyoFBs, DAPI nuclei within arteriolar SMA signal were considered VSMCs and
DAPI nuclei in non-arteriolar SMA signal were considered MyoFBs. The number of DAPI+pSMAD2+
VSMCs and the number of DAPI+pSMAD2+ MyoFBs were normalized by the total number of VSMCs
or MyoFBs, respectively, and expressed as a percentage. Finally, the percentages obtained in each
region were averaged within individuals. Measurements were performed on sections obtained from
the midpoint of the infarct.
3D fully automated microvasculature image analysis
Transverse paraffin sections (15 mm) of infarcted hearts were stained with anti-CD31 and anti-SMA
antibodies and DAPI for nuclear staining. Two to four images were acquired within the IZ (including
the two most distal edges and the center of the IZ) per mouse with a Nikon A1R confocal micro-
scope. Thus, 38 3D images were quantified. Characterization of the microvasculature was performed
by means of a fully automated pipeline (Gkontra et al., 2018). Modules of the pipeline were
adapted as previously described (Żak et al., 2019) in order to account for the different animal model
(mouse) as well as the use of the relatively thin tissue sections compared to the thick tissue sections
of ~100 mm used in the original work. Moreover, since images included both tissue areas and areas
belonging to the microscope slide, it was necessary to separate the tissue volume from the back-
ground glass area. For this purpose, first the images were denoised by means of non-local means fil-
tering (Buades et al., 2005). Subsequently, 3D tissue segmentation was performed by applying
the Otsu multi-level thresholding technique (Otsu, 1979) on the nuclei channel. It should be noted
that the intensity levels used for thresholding varied between three and four depending on the
image and they were automatically defined. Voxels of all intensities levels but the lower one were
considered to belong to the tissue. Finally, holes within the segmented area were automatically iden-
tified and filled. It should be noted that apart from normalization purposes, the tissue mask was
used to exclude from the corresponding segmentation mask of vessels and SMA+ cells non-tissue
voxels that were incorrectly identified as belonging to vessels or SMA, respectively. To this end,
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element-wise multiplications of the segmentation of vessels and SMA+ cells with the tissue mask
were performed.
Following tissue segmentation, we applied modules of the pipeline that permit the automatic
segmentation of nuclei, vessels, and SMA+ cells from the corresponding image channels. Classifica-
tion of microvessels according to their size and relation with SMA+ cells into different physiologically
meaningful categories was performed as previously described (Żak et al., 2019). Finally, quantitative
parameters regarding the morphology and angioarchitecture of the network as well as the relation
of vessels with SMA+ cells were extracted. The parameters are summarized in Table 3.
Cell culture
Bone marrow-derived Mjs (BMDMs) were harvested from 8 to 10 week-old WT and MAC-Mmp14
KO mice by flushing femurs and tibias with PBS. Cells were filtered through a 100 mm nylon cell
strainer (Falcon) and cultured in RPMI (Lonza) supplemented with 20% L929-cell conditioned
medium, 10% FBS (Gibco), 1% penicillin and streptomycin (P/S, Lonza), and 1 mM L-Gln (Lonza) in
sterile non-tissue culture treated 10 cm Petri dish. BMDMs were grown to confluence and activated
overnight with 50 ng/mL LPS (Sigma) to stimulate TGFb1 production. The medium was then
replaced, and after incubation for 48 hr, the supernatant was harvested, centrifuged, and stored at
 20˚C until use in co-culture experiments. BMDMs were polarized towards the M1 or M2 phenotype
by incubation for 24 hr with 10 ng/mL LPS (Sigma) or 10 ng/mL IL4 (Peprotech), respectively.
Mouse aortic endothelial cells (MAECs): Six to eight aortas from 4-week-old male C57BL/6 mice
were pooled to obtain a single-cell suspension (Fogelstrand et al., 2009). Briefly, after carefully
aorta dissection and fat removal under a microscope, aortas were incubated in collagenase type I
solution (3.33 mg/mL, Worthington) for 5 min at 37˚C. Then, adventitia was removed with forceps,
the aortas were then cut into small pieces (1–2 mm) and incubated for 45 min at 37˚C in a collage-
nase type I (6 mg/mL, Worthington) and elastase (2.5 mg/mL, Worthington) solution. The obtained
single-cell suspension was plated on 0.5%-gelatin-coated plates in DMEM/F12 supplemented with
20% FBS, 2 mM L-Gln, 1% P/S, and ECGS/H. When culture became confluent, MAECs were posi-
tively selected with an antibody against intercellular adhesion molecule 2 (anti-ICAM2, BD Bioscien-
ces) coupled to magnetic beads (Dynabeads Sheep Anti-Rat IgG, ThermoFisher), and cultured as
indicated in M199 supplemented with 20% FBS, 1% P/S, 2 mM L-Gln 1% HEPES, and ECGS/H
(Koziol et al., 2012).
Cardiac FBs were isolated from 8-week-old C57BL/6 mice as previously described (Brand et al.,
2010). Briefly, hearts were sequentially incubated in a solution containing collagenase type II (0.48
mg/mL, Worthington) and porcine pancreatin (2.5 mg/mL, Sigma) at 37˚C in a water bath with gentle
shaking. Once tissue was completely disaggregated, cell fractions were resuspended in DMEM sup-
plemented with 10% FBS, 1% P/S, and 2 mM L-Gln. The cell suspension was then plated on 1%-gela-
tin-coated plates and incubated at 37˚C for 1 hr to allow FBs to attach. The supernatant, enriched in
the myocyte fraction, was then removed and replaced with a fresh medium.
Neonatal CMs were isolated from P1-P3 C57BL/6 pups as previously described (Brand et al.,
2010). Briefly, 25–30 neonates were sacrificed, and hearts were digested in a solution containing col-
lagenase type II (0.48 mg/mL, Worthington) and porcine pancreatin (2.5 mg/mL, Sigma) at 37˚C in a
water bath with gentle shaking. Once the tissue was completely segregated, cell fractions were
resuspended in DMEM supplemented with 10% M199 medium, 15% FBS, 0.5% HEPES, 1% P/S, and
2 mM L-Gln. The cell suspension was then plated on 1%-gelatin-coated plates and incubated at 37˚C
for 1 hr to remove FBs through attachment to the plate. The supernatant, enriched in the myocyte
fraction, was then centrifuged and, resuspended in the same medium, and CMs were plated on 1%-
gelatin–coated plates. CM beating was observed in the cultures.
Human embryonic kidney 293 (HEK293) cells (Lonza) were cultured in DMEM (Lonza) with 10%
FBS.
Cardiac Mjs: FACS-sorted Mjs (CD45+CD11b+F4/80+Ly6Clow cells) were purified from WT and
MAC-Mmp14 KO hearts on day 7 after MI. They were cultured in DMEM 10% FBS 10 ng/mL M-CSF
(Peprotech).
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Cell extract preparation and western blot analysis
WT or MAC-Mmp14 KO BMDMs were treated with 1 ng/mL LPS (Sigma) for 24 hr to stimulate
TGFb1 production. Prior to lysate collection, cell viability was determined by microscopy under
bright field and cell debris removed by two washes of monolayers with PBS. For preparation of total
lysates, 4  106 BMDMs were incubated in RIPA buffer, containing 50 mM Tris-HCl, pH 8; 150 mM
NaCl; 1% Triton X-100; 0.5% sodium deoxycholate; 0.1% SDS; 1 mM PMSF (Sigma), and a protease
and phosphatase inhibitor cocktail (Sigma), for 30 min at 4˚ C in the rotor. The lysate was centrifuged
(14,000 g, 10 min), and the supernatant containing the proteins was transferred to a new tube. For
subcellular fractioning, 4  106 BMDMs were incubated in HES buffer, containing 20 mM HEPES, 1
mM EDTA, 250 mM sucrose, and a protease and phosphatase inhibitor cocktail (Sigma), for 10 min
at 4˚ C. Cells were lysed through a 22G needle followed by a 25G needle, and centrifuged at 500 g
for 8 min to pellet the unbroken cells. Then, the supernatant was transferred to an empty tube and
centrifuged at 10,000 g for 12 min to separate the cytosolic (supernatant) and the membrane (pellet)
protein fractions.
Protein concentration was estimated using Bradford Assay (Bio-Rad) and 30 mg of total protein
were separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad). Correct
protein loading was confirmed by Ponceau staining. Membranes were incubated overnight with anti-
bodies against TGFb1 (Santa Cruz), TfR (Abcam), and a-tubulin (Sigma), and then thoroughly washed
and incubated with HRP-conjugated anti-rabbit (Jackson) or anti-mouse (Jackson) antibodies
(1:7500). Blots were visualized using the chemiluminescent Immobilon Classico Western HRP sub-
strate (Millipore). Chemiluminescent signal was detected using ImageQuant LAS 4000 and densitom-
etry analysis performed using ImageJ. The ratio between proteins of interest (TGFb1) and
endogenous control (TfR) was calculated for data normalization. Graphs represent fold change calcu-
lated based on normalized data.
HEK293 transfection and luciferase assay
HEK293 cells (40%–50% confluence) were transfected over 6 hr with the plasmid p3TP-lux
(Wrana et al., 1992) with 2.5M CaCl2 in HEPES buffered saline (HBS). This plasmid contains lucifer-
ase downstream of the PAI-1 promoter, therefore the luciferase activity is proportional to the pro-
duction of bioactive TGFb1 (Abe et al., 1994). Luciferase assay was carried out as described
(Abe et al., 1994). In brief, transfected HEK293 cells were plated at a density of 30,000 cells per
well in p96-well plates and allowed to adhere for 6 hr. Then, 10 ng/mL of recombinant TGFb1
(Peprotech) for the positive control, 40,000 WT BMDMs or 40,000 MAC-Mmp14 KO BMDMs (previ-
ously activated with 50 ng/mL LPS overnight) were added to the plate. After 24 hr of incubation,
cells were lysed with passive lysis buffer (Promega), and luciferase activity was assayed with the
Promega Luciferase Assay according to manufacturer’s instructions.
When the assay was carried out with cardiac Mjs, CD45+CD11b+F4/80+Ly6Clow cells were sorted
as indicated in Figure 1—figure supplement 1A-B from 7 days post-MI WT or MAC-Mmp14 KO
hearts. 50,000 cardiac Mjs were added to the previously transfected and plated HEKs (as indicated
above), and M-CSF (10 ng/mL) was kept in the medium for the 24 hr of culture to maintain cardiac
Mjs alive. Then, cells were lysed with passive lysis buffer (Promega), and luciferase activity was
assayed with the Promega Luciferase Assay according to manufacturer’s instructions.
Lentiviral transduction
The full-length MT1-MMP sequence (FL) or mutated version to disable catalytic activity (E240A) was
cloned into the SFFV-IRESGFP lentiviral backbone. Lentiviruses expressing Mock, MT1-MMP FL, or
MT1-MMP E240A were prepared and titered as previously described (Esteban et al., 2020). For
viral inoculation, we incubated MAC-Mmp14 KO BMDMs with the viral supernatants (MOI = 10) in
RPMI supplemented with 20% L929-cell-conditioned medium, 10% FBS, 1% P/S, and 1 mM L-Gln for
48 hr. GFP signal was detected by fluorescent microscopy in transduced BMDMs. We then removed
the viral supernatants and stimulated the cells with 50 ng/mL LPS overnight. Afterward, the media
was removed and cells were cultured in DMEM 10% FBS for 24 hr to obtain conditioned media. Con-
ditioned media was then added to HEK293 cells for luciferase assay as described above.
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Co-cultures and qPCR assay
FBs were plated at 500,000 per well on 1%-gelatin-coated p12-well plates in DMEM supplemented
with 10% FBS, 1% P/S, and 2 mM L-Gln, and allowed to attach for 2 hr. The medium was then
removed and FBs were treated with WT or MAC-Mmp14 KO BMDM supernatants for 72 hr. After-
ward, cells were lysed with TRIzol Reagent (Ambion) for RNA isolation.
CMs were plated at 200,000 per well on 1%-gelatin-coated p12-well plates in DMEM supple-
mented with 10% M199 medium, 15% FBS, 0.5% HEPES, 1% P/S, and 2 mM L-Gln. Once CM beat-
ing was observed (after 4 days of culture), cells were treated with WT or MAC-Mmp14 KO BMDM
supernatants for 72 hr. Afterward, cells were lysed with TRIzol Reagent (Ambion) for RNA isolation.
MAECs were plated at 150,000 per well on 0.5%-gelatin–coated optical p6-well plates in M199
supplemented with 20% FBS, 1% P/S, 2 mM L-Gln, 1% HEPES, and ECGS/H, and allowed to attach
for 6 hr. The medium was then removed and treatments were added in the same medium with
reduced serum (5% FBS). The MAEC cultures were overlaid with 250,000 LPS-activated WT or MAC-
Mmp14 KO BMDMs. Co-cultures were maintained for 4 days. As a positive control for EndMT,
MAEC monocultures were treated with 10 ng/mL TGFb1. Afterward, cells were lysed with TRIzol
Reagent (Ambion) for RNA isolation following manufacturer’s instructions.
Co-culture and immunofluorescence assay
MAECs were plated at 20,000 per well on 0.5%-gelatin–coated optical p96-well plates in M199 sup-
plemented with 20% FBS, 1% P/S, 2 mM L-Gln, 1% HEPES, and ECGS/H, and allowed to attach for 6
hr. The medium was then removed and treatments were added in the same medium with reduced
serum (5% FBS). The MAEC cultures were overlaid with 30,000 LPS-activated WT or MAC-Mmp14
KO BMDMs, or with 50,000 cardiac Mjs from 7 days post-MI WT or MAC-Mmp14 KO mice. MAECs
were also treated with TGFb1 (10 ng/mL) and/or neutralizing aTGFb1 antibody (100 mg/mL). Co-cul-
tures were maintained for 4 days.
After two washes in HBBS, cultures were fixed for 10 min at room temperature (RT) in 4% parafor-
maldehyde. Cells were then permeabilized for 10 min at RT in 0.2% Triton X-100 in phosphate-buff-
ered saline (PBS) and blocked for 1 hr at RT in 5% goat serum and 5% BSA in PBS. After overnight
incubation with primary antibodies at 4˚ C in 2.5% goat serum and 2.5% BSA in PBS, cells were
washed three times with PBS at RT and then incubated with secondary antibodies and DAPI for 1 hr
30 min at RT in 2.5% goat serum and 2.5% BSA in PBS. Cells were then washed four times with PBS.
Cells were visualized under a Nikon A1R microscope, and images were acquired as 2  2 tile scans
of 5  1 mm sections. Maximum intensity projections were used for quantifications.
Statistics
Data are presented as mean ± SEM. Unpaired t-test was used when two groups were compared,
and a comparison of more than two sets of data was done using analysis of variance (ANOVA) with
Tukey’s post-test. All statistical analyses were performed using Prism v7 (GraphPad Software,
La Jolla, CA). Differences were considered significant when p<0.05, and represented as *p<0.05,
**p<0.01, ***p<0.001, and ****p<0.0001.
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La Residencia de Estudiantes Álvaro Sahún-Español
FORD-Spain and Apadrina La
Ciencia
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All data generated or analysed during this study are included in the manuscript and supporting files.
Source data files have been provided for all the figures.
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De Palma M, Ibáñez B, Arroyo AG. 2019. Sequential Bone-Marrow cell delivery of VEGFA/S1P improves
vascularization and limits adverse cardiac remodeling after myocardial infarction in mice. Human Gene Therapy
30:893–905. DOI: https://doi.org/10.1089/hum.2018.194, PMID: 30786776
Zavadzkas JA, Mukherjee R, Rivers WT, Patel RK, Meyer EC, Black LE, McKinney RA, Oelsen JM, Stroud RE,
Spinale FG. 2011. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial
infarction causes changes in survival, cardiac function, and remodeling. American Journal of Physiology-Heart
and Circulatory Physiology 301:H1656–H1666. DOI: https://doi.org/10.1152/ajpheart.00141.2011,
PMID: 21666120
Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT,
Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. 2007. Endothelial-to-mesenchymal transition
contributes to cardiac fibrosis. Nature Medicine 13:952–961. DOI: https://doi.org/10.1038/nm1613,
PMID: 17660828
Zhang Z, Wang JA, Xu Y, Jiang Z, Wu R, Wang L, Chen P, Hu X, Yu H. 2013. Menstrual blood derived
mesenchymal cells ameliorate cardiac fibrosis via inhibition of endothelial to mesenchymal transition in
myocardial infarction. International Journal of Cardiology 168:1711–1714. DOI: https://doi.org/10.1016/j.ijcard.
2013.03.126, PMID: 23608402
Alonso-Herranz et al. eLife 2020;9:e57920. DOI: https://doi.org/10.7554/eLife.57920 30 of 30
Research article Immunology and Inflammation Stem Cells and Regenerative Medicine
